This is a working overview of Cyclic AMP, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-29. Anything still debated is marked as such rather than presented as settled.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
== Signs and symptoms == Clinically, patients affected with HCP present similarly to those with other acute porphyrias, such as acute intermittent porphyria (AIP) and variegate porphyria (VP). Patients with HCP and VP can present with symptoms shared between the acute and cutaneous porphyrias. This includes the acute attacks of abdominal pain, nausea, vomiting, diarrhea, tachycardia, hypertension and seizures, as well as the cutaneous findings seen in porphyria cutanea tarda (PCT), namely increased skin fragility, bullous lesions after exposure to sunlight and increased scarring. Individuals with HCP may be asymptomatic in the absence of triggering factors. Common triggers include certain drugs, alcohol, hormonal changes, and dietary changes. Sunlight and other ultraviolet light can trigger the skin manifestations. Homozygous individuals for CPOX mutations can present with these findings at an earlier age than heterozygotes.
== Additional application == Acetoacetyl-CoA also behaves as a product of acetoacetyl-CoA synthetase (AACS) within the cytosol, using acetoacetate as the substrate, the reaction provides acetyl groups for lipogenesis. Understanding acetoacetyl-CoA is important in cholesterol development and lipogenesis and Acetoacetyl-CoA synthetase playing a role in its development, it also plays a significant role within the brain. Cholesterol and fats have been observed in high concentrations within neuronal tissue, as well as high AACS mRNA expression levels within cells of the hippocampus and cortical region. In addition, they play a significant role in neuronal development during the early embryonic and fetal developmental stages.
1993/1661) Immigration Appeals (Procedure) (Amendment) Rules 1993 (S.I. 1993/1662) Offshore Installations (Safety Zones) (No. 2) Order 1993 (S.I. 1993/1664) Recreation Grounds (Revocation of Parish Council Byelaws) Order 1993 (S.I. 1993/1665) Merchant Shipping (Fees) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1676) Export of Goods (Control) (Haiti) Order 1993 (S.I. 1993/1677) Immigration (Transit Visa) Order 1993 (S.I. 1993/1678) Income Support (General) Amendment No. 3 Regulations 1993 (S.I. 1993/1679) Merchant Shipping (Prevention of Oil Pollution) (Amendment) Regulations 1993 (S.I. 1993/1680) Merchant Shipping (Prevention of Pollution by Garbage) (Amendment) Regulations 1993 (S.I. 1993/1681) Diseases of Animals (Seizure) Order 1993 (S.I. 1993/1685) Road Traffic Act 1991 (Commencement No. 6 and Transitional Provisions) (Amendment) Order 1993 (S.I. 1993/1686) Football Spectators Act 1989 (Commencement No. 4) Order 1993 (S.I. 1993/1690) Football Spectators (Designation of Football Matches in England and Wales) Order 1993 (S.I. 1993/1691) Export of Goods (Control) (Amendment No. 2) Order 1993 (S.I. 1993/1692) Road Traffic Offenders (Prescribed Devices) Order 1993 (S.I. 1993/1698)
Blood coagulation: prothrombin (factor II), factors VII, IX, and X, and proteins C, S, and Z Bone metabolism: osteocalcin, matrix Gla protein (MGP), periostin, and Gla-rich protein. Vascular biology: Matrix Gla protein, growth arrest – specific protein 6 (Gas6) Unknown functions: proline-rich γ-carboxyglutamyl proteins 1 and 2, and transmembrane γ-carboxy glutamyl proteins 3 and 4.
Sources: en.wikipedia.org
=== 2008 === While running at training after round Four in 2008, Davey twisted and injured his right knee when changing direction, requiring immediate surgery and making him unavailable for the rest of the season because this would require him to miss between 6 and 12 months. Despite the injury, Davey continued to train but coach Matthew Knights did not risk him.
=== Cathinones === Cathinones include some stimulants and entactogens, which are derivatives of cathinone. They feature a phenethylamine core with an alkyl group attached to the alpha carbon, and a ketone group attached to the beta carbon, along with additional substitutions.
In 1952, retired chicken incubator salesman George W. Church Sr. opened the first Church's Chicken, named Church's Fried Chicken To-Go, in San Antonio, Texas. Initially, Church's Chicken was a single walk-up establishment that sold only fried chicken. Two pieces of chicken and a roll cost 49 cents. Church's Chicken added fries and jalapeños to its menu in 1955. To allow customers to see their food prepared while they waited, Church Sr. designed the kitchen with the fryers next to the takeout window.
Sources: en.wikipedia.org
As early as 1929, the tuberculostearic acid, molecular formula C19H38O2) was discovered, which was isolated from the tuberculosis pathogen Mycobacterium tuberculosis. In analogy to its name, the biochemists suggested the English name 'lactobacillic acid', as the fatty acid originated from a Lactobacillus species. Lactobacillic acid has also been isolated from L. casei. In the publication, the scientists emphasized the implications of their discovery, which contradicted the opinion at the time that only fatty acids with an even number of carbon atoms occur in nature.
== Geography == According to the United States Census Bureau, the city has an area of 2.70 square miles (6.99 km2); 2.67 square miles (6.92 km2) is land and 0.03 square miles (0.08 km2) is water. The Sauk River bisects Cold Spring from the southwest. Cold Spring is in Wakefield Township geographically but is a separate entity.
== Mode of action classification == IRAC publishes an insecticide mode of action (MoA) classification that lists most common insecticides and acaricides and recommends that "successive generations of a pest should not be treated with compounds from the same MoA Group". IRAC assigns a mode of action (MoA) to an insecticide, based on sufficient scientific data. They then update the mode of action (MoA) classification. Several insecticides and classes of insecticide may act through the same mode of action.
=== Stagg Damages === Stagg sued the police for damages totalling £1 million following the fourteen months he spent in custody. He has co-written and published two books about the case: Who Really Killed Rachel? (with novelist David Kessler) and, more recently, Pariah (with journalist Ted Hynds), the latter being published on the same day as the real culprit's appearance in court to enter a plea. In January 2007, the Home Office confirmed that Stagg would receive compensation for wrongful prosecution, with the amount to be set by an independent assessor. On 13 August 2008, it was announced that the compensation was £706,000. In December 2008, Colin Stagg finally received a public apology from the Metropolitan Police for their previous involvement and prosecution of him in regard to the Nickell murder investigation. He also received an apology from Robert Napper, delivered via his QC.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.